Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04680468 · ClinicalTrials.gov registry record · Phase 2
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
A Phase 2 study of Myeloma, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT04680468 is a Phase 2 study of Myeloma that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 41 participants, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04680468, a Phase 2 study of Myeloma, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous stem cell transplant consolidation and maintenance will be safe, well tolerated, and efficacious in comparison to historical data.
Conditions Studied
Interventions
- DRUG Belantamab mafodotin
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2026-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04680468
The ClinicalTrials.gov registry entry for NCT04680468 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (58% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Belantamab mafodotin is the first listed.
NCT04680468 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04680468 about?
NCT04680468 is a clinical study titled "Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma". This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transp...
What is the current status of trial NCT04680468?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2021-06-02. Estimated completion is 2026-07-11.
What conditions does trial NCT04680468 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT04680468?
The interventions under investigation include: Belantamab mafodotin (DRUG).
Who is sponsoring clinical trial NCT04680468?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04680468 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
RECRUITING · Phase 2
-
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.